8 results about "Aprepitant" patented technology

Disclosed are a pharmaceutical composition, an aprepitant injection, and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer, and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate and the secondary stabilizer comprises povidone. The aprepitant injection can be administered by injecting. The formulation uses a largely reduced amount of excipients, and is less irritative to an injection site, less prone to cause a hypersensitive reaction, and thus safer when being used by a patient. The formulation has good stability and can be stored and transported at room temperature, largely reducing production, storage, and transportation costs.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a stable aprepitant injection and a preparation method thereof. The aprepitant injection comprises the following raw materials in percentage by mass: 0.5-1% of aprepitant, 8-12% of soybean oil, 8-12% of egg yolk lecithin, 0.05-2% of egg yolk phosphatidyl glycerol, 0.5-0.8% of sodium oleate, 5-8% of cane sugar, 2-4% of ethanol and the balance of water for injection, totaling 100%. The selected co-emulsifier egg yolk phosphatidyl glycerol has two hydroxyl groups at the hydrophilic end, so that the egg yolk phosphatidyl glycerol has extremely strong emulsifying performance, is well compatible with aprepitant, has a good emulsifying effect of the preparation, and can well encapsulate aprepitant, so that the dosage of egg yolk lecithin is reduced by about one third, and the stable drug-loaded fat emulsion is formed; the preparation method is suitable for industrial production, the preparation cost is low, and the accessibility of the medicine is improved.

The present disclosure provides pharmaceutical formulations including aprepitant that are suitable for intravenous administration, including lyophilized formulations, processes for the preparation thereof, and their use in the treatment or prevention of emesis.

The present invention relates to an emulsion including aprepitant, an emulsifier, an oil, polyethylene glycol, and water, without substantial addition of ethanol.

The application discloses a pharmaceutical composition, an aprepitant injection and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate, and the secondary stabilizer comprises povidone. The aprepitant injection provided by the application can be injected for administration, the dosage of auxiliary materials is greatly reduced, the injection site is less irritating when used by patients, and the aprepitant injection is less likely to cause hypersensitivity reaction and is safer; the preparation has good stability, can be stored and transported at room temperature, and greatly reduces the production, storage and transportation costs.

The present invention relates to an injectable composition comprising aprepitant and at least one pharmaceutically acceptable excipient. The invention further relates to processes for preparing such injectable compositions and to their use in the prevention or treatment of emesis, including but not limited to chemotherapy- induced or postoperative nausea and vomiting.

The present disclosure provides a compound emulsion for injection of aprepitant and palonosetron hydrochloride. The compound emulsion has good stability and is more convenient and effective in preventing and treating nausea and vomiting, which improves patient medication adherence.

Provided is a process for preparing an emulsion having an oil phase containing an emulsifier, an oil, a drug, and a co-emulsifier, and an aqueous phase containing water, a tonicity agent, and a pH modifier, without removing excess co-emulsifier after emulsification. The process includes emulsifying an oil phase containing an oil, aprepitant, an egg lecithin, and ethanol, and an aqueous phase containing water, sucrose, and oleic acid or salt thereof, without removing ethanol after emulsification. The drug is added to the oil phase as a dry mixture containing the drug and a co-emulsifier (e g., ethanol).